Australian recommendations for the management of hepatitis C virus infection: a consensus statement.

@article{Thompson2016AustralianRF,
  title={Australian recommendations for the management of hepatitis C virus infection: a consensus statement.},
  author={Alexander J Thompson},
  journal={The Medical journal of Australia},
  year={2016},
  volume={204 7},
  pages={268-72}
}
Chronic hepatitis C virus (HCV) infection affects 230 000 Australians, who are at risk of progressive liver fibrosis leading to cirrhosis, liver failure and hepatocellular carcinoma. HCV infection is curable, and all Australians living with HCV should be considered for antiviral therapy. Interferon-free regimens involving combinations of sofosbuvir, ledipasvir, daclatasvir and/or ribavirin for 8, 12 or 24 weeks are now listed on the Pharmaceutical Benefits Scheme (PBS) for treating people with… CONTINUE READING